Ostarine (MK-2866): A Complete SARM Guide

Ostarine, also known as MK-2866 or enobosarm, is the most extensively studied selective androgen receptor modulator (SARM) in the published literature. Originally developed by GTx, Inc. for the treatment of muscle-wasting conditions and cachexia, it has accumulated more human clinical trial data than any other compound in its class. For researchers entering the SARM category, Ostarine is frequently cited as the reference point against which other non-steroidal anabolic agents are benchmarked.

What Ostarine Is

Ostarine is a non-steroidal SARM that binds to androgen receptors (AR) with tissue-selective activity. Unlike testosterone and its derivatives, which act broadly across androgen receptors throughout the body, SARMs were designed to exploit differential expression patterns in muscle and bone tissue versus prostate, liver, and sebaceous glands. The pharmacological goal, as described in early development papers from GTx and collaborating academic groups, was to reproduce the anabolic effects of androgens on lean mass and bone mineral density without the full spectrum of androgenic activity associated with exogenous testosterone.

Structurally, Ostarine is a small-molecule aryl-propionamide derivative. It is orally bioavailable, with a reported half-life in the range of 24 hours in human subjects, making once-daily administration the convention in clinical protocols. Its mechanism is partial agonism at the androgen receptor — it activates AR-mediated transcription in muscle and bone at dose ranges that produce minimal activation in prostate tissue in the studies conducted to date.

It is important to note for researchers that Ostarine has not been approved by the FDA, Health Canada, or the EMA for any therapeutic indication. It is classified as a research compound. The World Anti-Doping Agency (WADA) has banned it for use in competitive sport since 2008, and it appears on the S1 Anabolic Agents list.

The Clinical Evidence Base

What distinguishes Ostarine from most other SARMs is the depth of its human trial record. The compound progressed through Phase I, Phase II, and Phase III clinical trials, primarily targeting cancer-related cachexia, sarcopenia in elderly populations, and stress urinary incontinence in postmenopausal women.

The most frequently cited dataset comes from Dalton et al. (2011), a 12-week Phase II trial published in the Journal of Cachexia, Sarcopenia and Muscle. In that study, 120 healthy elderly men and postmenopausal women received Ostarine at doses of 0.1, 0.3, or 3 mg daily. The 3 mg group showed a mean increase in total lean body mass of approximately 1.3 kg compared with placebo, along with improvements in stair-climb power — a functional measure. This was achieved without resistance training, which is notable when contextualizing dose-response.

Subsequent Phase III work in cachexia populations — the POWER trials conducted in patients with non-small-cell lung cancer — evaluated Ostarine at 1 mg and 3 mg daily. The trials met their co-primary endpoint for lean body mass but did not meet the physical function endpoint to the satisfaction of the FDA, which contributed to the compound not advancing to approval. Regardless of regulatory outcome, the trials generated safety and efficacy data at sustained daily dosing over several months, which remains valuable for researchers designing protocols.

A separate body of work in postmenopausal women, reported in published Phase II data, examined Ostarine's effect on bone mineral density and lean mass at doses up to 3 mg daily over 3 months, with preserved bone turnover markers reported in the active groups.

Reported Dose Ranges in the Literature vs. Applied Research Use

Clinical trial doses for Ostarine clustered in the 1–3 mg daily range. In the research-compound community and in recreational applied-use literature — which is distinct from peer-reviewed data and should be treated as anecdotal — the commonly cited range is 15–25 mg per day, taken once daily, orally, over a cycle length of 8–12 weeks.

This discrepancy between clinical trial doses and applied-use doses is substantial and deserves explicit acknowledgment. The 15–25 mg range comes from user-reported protocols aggregated across forums and non-clinical sources. There is no published human trial at these doses with matched duration. Researchers evaluating this range are working outside the bounds of the controlled clinical dataset.

Within the applied-use literature, reported dosing patterns break down approximately as follows:

• 10–15 mg daily: described in user reports for muscle preservation during caloric deficit (a "cutting" context)
• 15–20 mg daily: the most commonly reported recomposition range
• 20–25 mg daily: upper end, typically reserved for lean-mass accrual in a caloric surplus
• 25 mg daily and above: reported but associated in anecdotal reports with more pronounced suppression and lipid changes

Ostarine's 24-hour half-life means that once-daily dosing produces stable serum concentrations; splitting the dose is not pharmacokinetically necessary and is not standard in either clinical or applied protocols.

Cycle Length and the Suppression Question

Ostarine cycles in the applied-use literature are commonly reported at 8–12 weeks — longer than the 4–8 week cycles described for more suppressive SARMs such as RAD-140 or LGD-4033. The rationale given is that Ostarine produces milder suppression of the hypothalamic-pituitary-gonadal (HPG) axis at standard research doses, which is thought to permit extended administration.

The clinical data supports partial suppression. In the Dalton 2011 study and related Phase II reports, total testosterone and sex hormone-binding globulin (SHBG) decreased from baseline in the active dose groups, with the magnitude scaling with dose. These changes were reversible after cessation. Free testosterone suppression was also observed but was described as modest relative to what is typical with exogenous testosterone or with more potent SARMs.

Importantly, "mild suppression" is not "no suppression." Researchers evaluating cycles at the upper end of the applied dose range (20–25 mg) for 10–12 weeks should anticipate meaningful reductions in endogenous testosterone production and in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) based on the mechanism and the observed dose-response in clinical work.

Post-Cycle Protocols in Applied Research

Post-cycle therapy (PCT) for Ostarine is a contested topic in the applied-use literature. At clinical doses (1–3 mg), recovery of endogenous hormone production was reported within several weeks of cessation without pharmacological intervention. At applied doses (15–25 mg) over 8–12 weeks, reports diverge.

Some protocols describe no PCT as necessary, relying on natural recovery. Others describe a low-dose selective estrogen receptor modulator (SERM) protocol — typically tamoxifen or clomifene at reduced doses relative to what follows a traditional anabolic-steroid cycle. A frequent pattern in applied literature is a brief SERM course of 4 weeks at reduced dosing.

There is no published clinical data validating any specific PCT approach following Ostarine administration at applied-use doses. Researchers should consult baseline and post-cycle bloodwork — including total and free testosterone, LH, FSH, and SHBG — rather than relying on symptomatic assessment alone.

Lipid and Liver Markers

Across the clinical trial dataset, Ostarine produced measurable changes in lipid panels. The most consistent finding was a reduction in high-density lipoprotein (HDL) cholesterol, reported in the Phase II work at 3 mg daily. The magnitude was described as modest in clinical-dose studies but scales with dose in a manner consistent with androgen receptor activation in the liver.

At applied-use doses in the 20–25 mg range over 8–12 weeks, user-reported bloodwork frequently describes HDL reductions in the range of 20–40%, along with smaller increases in low-density lipoprotein (LDL). Total cholesterol may remain relatively stable while the ratio shifts unfavorably. These reports are not from controlled studies but represent a consistent signal across aggregated self-reported data.

Liver enzyme elevations (ALT and AST) have been reported in a subset of users at applied doses. In the clinical record, a small number of case reports have described drug-induced liver injury associated with Ostarine products obtained outside of regulated clinical supply, though impurity and mislabeling in grey-market products confound interpretation. Baseline and mid-cycle liver panels are a standard recommendation in the applied-use literature.

Muscle Preservation During Caloric Deficit

One of the most frequently cited applications for Ostarine in the research-compound context is muscle preservation during caloric deficit — the "cutting" use case. The rationale draws on the Phase II and Phase III cachexia trials, where Ostarine preserved or increased lean body mass in populations experiencing disease-driven muscle loss.

Extrapolating this finding to voluntary caloric restriction in otherwise healthy subjects is reasonable mechanistically but has not been directly tested in published human trials. The cachexia population experiences muscle loss driven by inflammatory cytokines and catabolic signaling that differs from simple energy-deficit-driven loss. Researchers applying this rationale should recognize the extrapolation.

In the applied-use literature, the dose range reported for this application is typically at the lower end — 10–15 mg daily — with the stated goal of preservation rather than accrual. Cycle length in cutting contexts often matches the duration of the caloric deficit, with 8-week cycles being common.

Stacking and Comparisons

Ostarine is frequently compared against Cardarine (GW-501516, a PPAR-delta agonist, not a SARM), LGD-4033, and RAD-140 in the applied-use literature. It is positioned as the entry-level compound of the SARM category on the basis of its milder suppression profile, extensive clinical dataset, and lower reported incidence of side effects at standard research doses.

Stacking protocols — combining Ostarine with other research compounds — sit entirely outside the clinical evidence base. Any such combination is extrapolation from single-agent data. The research-compound community commonly describes Ostarine paired with Cardarine for endurance-and-recomposition contexts, but there are no controlled human studies of combined administration.

For researchers interested in the peptide category as an adjacent area, compounds like BPC-157 address different mechanisms entirely (tissue repair rather than androgen receptor modulation) and are not pharmacologically comparable.

What to Read Next

Researchers building a foundational understanding of the SARM category may find it useful to compare Ostarine's profile against LGD-4033 (Ligandrol), which has a shorter clinical record but higher reported potency, and against RAD-140 (Testolone), which exhibits a different suppression and lipid profile. Reading the original Dalton 2011 paper and the publicly available POWER trial summaries provides direct access to the primary human data rather than aggregated secondary sources.

Open questions in the Ostarine literature include the long-term (beyond 12 months) effects of repeated cycling, the dose-response relationship above 3 mg daily in controlled settings, and the degree to which tissue selectivity is preserved at applied-use doses. None of these have been directly addressed in published human trials, and researchers evaluating the compound should weigh that absence when designing protocols.